Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.
CITATION STYLE
Apra, C., Dumot, C., Bourdillon, P., & Pelissou-Guyotat, I. (2019, June 1). Could propranolol be beneficial in adult cerebral cavernous malformations? Neurosurgical Review. Springer Verlag. https://doi.org/10.1007/s10143-018-01074-0
Mendeley helps you to discover research relevant for your work.